エラーが発生しました。 詳細 隠す
保存されていないページがあります。 復元 取り消す

Biotechnology Innovation Organization

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

すべてのデータセット:  B E V
  • B
    • 6月 2018
      ソース: Biotechnology Innovation Organization
      アップロード者: Knoema
      以下でアクセス: 11 9月, 2018
      データセットを選択
      This eighth, biennial report focuses on the economic progress and footprint of the industry geographically including the performance, positioning and latest trends in the bio-science industry for the nation, states and metropolitan areas. For the first time, it includes a national assessment of the full economic impact of the bio-science industry not only in terms of employment, but also with respect to economic output and fiscal impacts. In addition, the report details the nation’s academic research activities and trends in federal funding, access to critical angel and venture capital and the innovation outputs context via patent activities.
  • E
  • V
    • 2月 2016
      ソース: Biotechnology Innovation Organization
      アップロード者: Knoema
      以下でアクセス: 02 5月, 2016
      データセットを選択
      Access to early-stage financing is the lifeblood of biotechnology innovation. For therapeutic-focused biotechnology companies in particular, the required capital and development timelines dwarf most other industries, making it challenging to find sizable early investments from committed investors. As the world’s largest trade association representing biotechnology companies across the United States and in more than 30 other nations, it is important for BIO to better understand investor trends in order to determine where scientific or policy issues may be impacting the ability to maintain a robust pipeline of innovative medicines.